MPNConnect—your resource for information about the JAK signaling pathway in MPNs
Dear Dr [Last name],
Thank you for registering to become a member of MPNConnect. Continue to visit MPNConnect.org for regular updates on dysregulated Janus kinase (JAK) signaling—a key pathogenic mechanism of three Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs):
Three frequent mutations have been associated with these diseases: JAK2V617F, JAK2 exon 12 mutations and MPL mutations. However, there are multiple causes of dysregulated JAK signaling.
Other mechanisms of dysregulated JAK signaling include excess cytokines, increased JAK1 signaling, loss of negative regulation of JAKs and undiscovered mutations.Continue to visit MPNConnect for updates on emerging scientific advances in MPNs. As a member you can now view or download the JAK Pathway Signaling in MPNs video.
Sincerely,
MPNConnect
 |
| JAK Pathway Signaling and MPNs |
 |
| JAK Pathway in MPNs |
If you no longer wish to receive email communication from MPNConnect, an Incyte Corporation Web site, please unsubscribe.
You can also opt out of communications from MPNConnect by sending a request to:
Incyte Corporation
Commercial Operations Department
Experimental Station
Route 141 & Henry Clay Road
Building E336
Wilmington, DE 19880
